T. Breen

发表

B5-01: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023

Cynthia S. Johnson, C. Yiannoutsos, N. Hanna, 2007 .

A Phase I/II Trial of BNC105P with Everolimus in Metastatic Renal Cell Carcinoma

B. Costello, G. Sonpavde, H. Drabkin, 2015, Clinical Cancer Research.

A Phase I / II Trial of BNC 105 P with Everolimus in Metastatic Renal Cell Carcinoma

B. Costello, G. Sonpavde, H. Drabkin, 2015 .

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)

T. Choueiri, G. Sonpavde, M. Regan, 2018, British Journal of Cancer.

Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102.

J. Picus, E. Chiorean, P. Loehrer, 2015 .

Gefitinib Plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer: A Phase II Study from the Hoosier Oncology Group

N. Hanna, Menggang Yu, L. Einhorn, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157

E. Plimack, A. Ross, G. Netto, 2016, Clinical Cancer Research.

Phase I feasibility trial of stereotactic body radiation therapy for primary hepatocellular carcinoma

S. Perkins, P. Kwo, H. Cárdenes, 2010, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.

Cynthia S. Johnson, Constantin Yiannoutsos, Thomas Anderson, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

G. Sonpavde, M. Galsky, Liang Cheng, 2016, Urologic oncology.

Prognostic factors in stage III non-small-cell lung cancer.

Cynthia S. Johnson, N. Hanna, F. Ademuyiwa, 2007, Clinical Lung Cancer.

Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study

Cynthia S. Johnson, N. Hanna, L. Einhorn, 2016, Supportive Care in Cancer.

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum‐resistant ovarian cancer and primary peritoneal carcinomatosis

D. Matei, J. Schilder, C. Whalen, 2008, Cancer.

A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial.

M. Fleming, G. Sonpavde, M. Galsky, 2012 .

Activity of 2 methoxyestradiol (Panzem NCD) in advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis: a Hoosier Oncology Group trial.

D. Matei, S. Perkins, J. Schilder, 2009, Gynecologic oncology.